Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Olivier, Lapujade"'
Autor:
Anne Rechtien, Laura Richert, Hadrien Lorenzo, Gloria Martrus, Boris Hejblum, Christine Dahlke, Rahel Kasonta, Madeleine Zinser, Hans Stubbe, Urte Matschl, Ansgar Lohse, Verena Krähling, Markus Eickmann, Stephan Becker, Selidji Todagbe Agnandji, Sanjeev Krishna, Peter G. Kremsner, Jessica S. Brosnahan, Philip Bejon, Patricia Njuguna, Marylyn M. Addo, Claire-Anne Siegrist, Angela Huttner, Marie-Paule Kieny, Vasee Moorthy, Patricia Fast, Barbara Savarese, Olivier Lapujade
Publikováno v:
Cell Reports, Vol 20, Iss 9, Pp 2251-2261 (2017)
Predicting vaccine efficacy remains a challenge. We used a systems vaccinology approach to identify early innate immune correlates of antibody induction in humans receiving the Ebola vaccine rVSV-ZEBOV. Blood samples from days 0, 1, 3, 7, and 14 were
Externí odkaz:
https://doaj.org/article/b6715c79bca245bab050971e0d2eb903
Autor:
Christine Dahlke, Rahel Kasonta, Sebastian Lunemann, Verena Krähling, Madeleine E. Zinser, Nadine Biedenkopf, Sarah K. Fehling, My L. Ly, Anne Rechtien, Hans C. Stubbe, Flaminia Olearo, Saskia Borregaard, Alen Jambrecina, Felix Stahl, Thomas Strecker, Markus Eickmann, Marc Lütgehetmann, Michael Spohn, Stefan Schmiedel, Ansgar W. Lohse, Stephan Becker, Marylyn M. Addo, Selidji Todagbe Agnandji, Sanjeev Krishna, Peter G. Kremsner, Jessica S. Brosnahan, Philip Bejon, Patricia Njuguna, Claire-Anne Siegrist, Angela Huttner, Marie-Paule Kieny, Kayvon Modjarrad, Vasee Moorthy, Patricia Fast, Barbara Savarese, Olivier Lapujade
Publikováno v:
EBioMedicine, Vol 19, Iss C, Pp 107-118 (2017)
Background: The recent West African Ebola epidemic led to accelerated efforts to test Ebola vaccine candidates. As part of the World Health Organisation-led VSV Ebola Consortium (VEBCON), we performed a phase I clinical trial investigating rVSV-ZEBOV
Externí odkaz:
https://doaj.org/article/d0ce2f1c3c5144fda4534dfdc5f9b942
Autor:
Piero Olliaro, Michel Vaillant, Byron Arana, Max Grogl, Farrokh Modabber, Alan Magill, Olivier Lapujade, Pierre Buffet, Jorge Alvar
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 7, Iss 3, p e2130 (2013)
The current evidence-base for recommendations on the treatment of cutaneous leishmaniasis (CL) is generally weak. Systematic reviews have pointed to a general lack of standardization of methods for the conduct and analysis of clinical trials of CL, c
Externí odkaz:
https://doaj.org/article/4095eff5c5754f3b90248ec3efdfd325
Autor:
Piero L Olliaro, Michel T Vaillant, Vincente J Belizario, Nicholas J S Lwambo, Mohamed Ouldabdallahi, Otavio S Pieri, Maria L Amarillo, Godfrey M Kaatano, Mamadou Diaw, Analucia C Domingues, Tereza C Favre, Olivier Lapujade, Fabiana Alves, Lester Chitsulo
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 5, Iss 6, p e1165 (2011)
Praziquantel at 40 mg/kg in a single dose is the WHO recommended treatment for all forms of schistosomiasis, but 60 mg/kg is also deployed nationally.Four trial sites in the Philippines, Mauritania, Tanzania and Brazil enrolled 856 patients using a c
Externí odkaz:
https://doaj.org/article/d7b0a7e8099b42c69f02ea08938e23b0
Autor:
Corinne S, Merle, Katherine, Fielding, Omou Bah, Sow, Martin, Gninafon, Mame B, Lo, Thuli, Mthiyane, Joseph, Odhiambo, Evans, Amukoye, Boubacar, Bah, Ferdinand, Kassa, Alimatou, N'Diaye, Roxana, Rustomjee, Bouke C, de Jong, John, Horton, Christian, Perronne, Charalambos, Sismanidis, Olivier, Lapujade, Piero L, Olliaro, Christian, Lienhardt, I, Zongo
Publikováno v:
New England Journal of Medicine. 371:1588-1598
BACKGROUND : Shortening the course of treatment for tuberculosis would be a major improvement for case management and disease control. This phase 3 trial assessed the efficacy and safety of a 4-month gatifloxacin-containing regimen for treating rifam
Autor:
Olivier Lapujade, Jorge Alvar, Michel Vaillant, Farrokh Modabber, Pierre Buffet, Max Grogl, Byron Arana, Alan J. Magill, Piero Olliaro
Publikováno v:
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, 2013, 7 (3), pp.e2130. ⟨10.1371/journal.pntd.0002130⟩
PLoS Neglected Tropical Diseases, Public Library of Science, 2013, 7 (3), pp.e2130. ⟨10.1371/journal.pntd.0002130⟩
PLoS Neglected Tropical Diseases, Vol 7, Iss 3, p e2130 (2013)
PLoS Neglected Tropical Diseases, 2013, 7 (3), pp.e2130. ⟨10.1371/journal.pntd.0002130⟩
PLoS Neglected Tropical Diseases, Public Library of Science, 2013, 7 (3), pp.e2130. ⟨10.1371/journal.pntd.0002130⟩
PLoS Neglected Tropical Diseases, Vol 7, Iss 3, p e2130 (2013)
The current evidence-base for recommendations on the treatment of cutaneous leishmaniasis (CL) is generally weak. Systematic reviews have pointed to a general lack of standardization of methods for the conduct and analysis of clinical trials of CL, c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23df45a45915988c5da9af6d90cdb92b
https://doi.org/10.1371/journal.pntd.0002130
https://doi.org/10.1371/journal.pntd.0002130
Autor:
John R. Horton, Francoise Portaels, Roxana Rustomjee, Corinne Merle, Joseph Odhiambo, Olivier Lapujade, Christian Lienhardt, M. Gninafon, Christian Perronne, Mame Bocar Lo, Denis A Mitchinson, Katherine Fielding, Oumou Bah Sow, Piero Olliaro, Charalambos Sismanidis
Publikováno v:
Trials, Vol 13, Iss 1, p 61 (2012)
Trials
Trials
Background There have been no major advances in tuberculosis (TB) drug development since the first East African/British Medical Research Council short course chemotherapy trial 35 years ago. Since then, the landscape for conducting TB clinical trials
Autor:
Mamadou Diaw, Godfrey M. Kaatano, Tereza Cristina Favre, Olivier Lapujade, Mohamed Ouldabdallahi, Otávio Sarmento Pieri, Nicholas J.S. Lwambo, Piero Olliaro, AnaLucia C. Domingues, Fabiana Alves, Michel Vaillant, Vincente Belizario, Lester Chitsulo, Maria Lourdes E. Amarillo
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 5, Iss 6, p e1165 (2011)
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases
Background Praziquantel at 40 mg/kg in a single dose is the WHO recommended treatment for all forms of schistosomiasis, but 60 mg/kg is also deployed nationally. Methodology/Principal Findings Four trial sites in the Philippines, Mauritania, Tanzania